Drug

Akt Inhibitor MK2206

CI-DRUG-00000046Explore in graph →NCIt C90581 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	1	45	—	—	Apr 15, 2008
Malignant Kidney Neoplasm	Phase2	Phase 2	1	2	—	—	Jan 27, 2011
Malignant Prostate Neoplasm	Phase2	Phase 2	1	2	—	—	Mar 17, 2011
Hodgkin Lymphoma	Phase2	Phase 2	0	2	—	—	2010-12
Leukemia	Phase2	Phase 2	0	4	—	—	2010-10

Curated evidence

Clinical evidence (10)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SETD2 Loss1
Akt Inhibitor MK2206 +

Clinical trials

Trials with this intervention (45)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–45 of 45 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01480154	Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer	active not recruiting	Phase 1	62	National Cancer Institute (NCI)NIH	1	Sep 9, 2026	clinicaltrials
NCT01251861	Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer	completed

PTEN V317FS1
Akt Inhibitor MK2206 + MEK Inhibitor CI-1040Combination	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1534 A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift m… (full text at CIViC) PMID 24504448 · Turajlic et al., 2014 · Open in CIViC	civic

PTEN V317FS1

Akt Inhibitor MK2206 + MEK Inhibitor CI-1040Combination

Cutaneous MelanomaALIAS

Predictive

Supports Sensitivity Response

accepted

EID1534

A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift m… (full text at CIViC)

PMID 24504448 · Turajlic et al., 2014 · Open in CIViC

civic

AKT1 E17K1
Akt Inhibitor MK2206	Malignant Breast Neoplasm	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID231 Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations. PMID 23888070 · Beaver et al., 2013 · Open in CIViC	civic

AKT1 E17K1

Akt Inhibitor MK2206

Malignant Breast Neoplasm

Predictive

Does Not Support Sensitivity Response

accepted

EID231

Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations.

PMID 23888070 · Beaver et al., 2013 · Open in CIViC

civic

AKT3 Overexpression1
Akt Inhibitor MK2206	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	4	accepted	EID1922 Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model. PMID 27297869 · Stottrup et al., 2016 · Open in CIViC	civic

AKT3 Overexpression1

Akt Inhibitor MK2206

Malignant Breast Neoplasm

Predictive

Supports Resistance

accepted

EID1922

Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model.

PMID 27297869 · Stottrup et al., 2016 · Open in CIViC

civic

PIK3CA E545K1
Akt Inhibitor MK2206 + PictilisibSubstitutes	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID710 PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model. PMID 23888070 · Beaver et al., 2013 · Open in CIViC	civic

PIK3CA E545K1

Akt Inhibitor MK2206 + PictilisibSubstitutes

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID710

PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.

PMID 23888070 · Beaver et al., 2013 · Open in CIViC

civic

PIK3CA H1047R1
Akt Inhibitor MK2206 + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID8364 Resistance of RKO cells, which harbor BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R, to vemurafenib monotherapy was abrogated by the addition of pan-AKT inhibitor MK-2206 in … (full text at CIViC) PMID 22180495 · Yang et al., 2012 · Open in CIViC	civic

PIK3CA H1047R1

Akt Inhibitor MK2206 + VemurafenibCombination

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID8364

Resistance of RKO cells, which harbor BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R, to vemurafenib monotherapy was abrogated by the addition of pan-AKT inhibitor MK-2206 in … (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

civic

PIK3CA Mutation1
Akt Inhibitor MK2206	Malignant Thyroid Gland Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID12720 In thyroid cancer cell lines, MK2206 selectively inhibited the proliferation of cells harboring PI3K/Akt pathway activating mutations (PIK3CA, PTEN, RAS or RET/PTC) with IC50 values mostly below or ar… (full text at CIViC) PMID 21289267 · Liu et al., 2011 · Open in CIViC	civic

PIK3CA Mutation1

Akt Inhibitor MK2206

Malignant Thyroid Gland Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID12720

In thyroid cancer cell lines, MK2206 selectively inhibited the proliferation of cells harboring PI3K/Akt pathway activating mutations (PIK3CA, PTEN, RAS or RET/PTC) with IC50 values mostly below or ar… (full text at CIViC)

PMID 21289267 · Liu et al., 2011 · Open in CIViC

civic

CCNE1 Amplification1
Akt Inhibitor MK2206 + DinaciclibCombination	Ovarian Serous Cystadenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1735 A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC	civic

CCNE1 Amplification1

Akt Inhibitor MK2206 + DinaciclibCombination

Ovarian Serous Cystadenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID1735

A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors

PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC

civic

KRAS G12D1
Akt Inhibitor MK2206	Pancreatic Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID937 Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximatel… (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC	civic

KRAS G12D1

Akt Inhibitor MK2206

Pancreatic Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID937

Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximatel… (full text at CIViC)

PMID 22025163 · Yap et al., 2011 · Open in CIViC

civic

PTEN Loss1
Akt Inhibitor MK2206	Pancreatic Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID938 Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% … (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC	civic

PTEN Loss1

Akt Inhibitor MK2206

Pancreatic Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID938

Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% … (full text at CIViC)

PMID 22025163 · Yap et al., 2011 · Open in CIViC

civic